Selective TRPV2 Blockers for Low-Cytotoxic Inflammation Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for new therapeutic agents effective in treating inflammation-mediated diseases, particularly inflammatory responses and cardiovascular disorders, as well as anti-cancer agents that can selectively inhibit TRPV2 activity without significant cytotoxicity.
Innovation Solution
Development of novel TRPV2 blockers, such as small molecules represented by specific chemical formulas, which inhibit TRPV2 activity in a highly selective manner, reducing TRPV2-expressing tumor viability while sparing healthy cells, and are administered in pharmaceutical compositions for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TRPV2 blockers are administered to inhibit TRPV2 activity in tumors, then tumor cell viability is reduced, but there is a risk of cytotoxicity to healthy cells
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target TRPV2 channels in tumor cells while sparing healthy cells. The compounds exhibit selective inhibition of TRPV2 in cancer cells due to differential TRPV2 expression levels between tumor and normal tissues, achieving localized therapeutic effect at the molecular level.
Solution Approach 2:
The patent utilizes parameter changes by optimizing the chemical structure of TRPV2 blockers to achieve selective binding affinity. The compounds are designed with specific molecular parameters (structure-activity relationship) that enable preferential interaction with TRPV2 channels in tumor cells, changing the selectivity parameter to favor cancer cell inhibition over healthy cell toxicity.
2Reliability
If existing TRPV2 inhibitors are used to treat inflammatory diseases, then some therapeutic effect is achieved, but they exhibit substantial cytotoxicity and limited selectivity
Solution Approach 1:
The patent creates improved copies of existing TRPV2 inhibitors by developing novel chemical compounds (Formulas I-VII) that replicate and enhance the therapeutic effects of known inhibitors while eliminating their cytotoxic side effects. The new compounds are designed based on structure-activity relationship studies to optimize the therapeutic index.
Solution Approach 2:
The patent employs composite materials by designing molecules with multiple functional groups and structural features that work synergistically. The compounds contain specific structural elements (aromatic rings, heterocyclic groups, substituent patterns) that collectively provide selective TRPV2 inhibition with reduced cytotoxicity, achieving superior safety profile compared to single-feature inhibitors.
Data Source
AI summary
The present invention involves novel TRPV2 blockers, pharmaceutical compositions comprising the same and uses thereof for the treatment of inflammatory response in inflammation mediated disease processes.